New book by Larry Connors Click here Improve your trading - See how
(Logo: http://www.newscom.com/cgi-bin/prnh/20091104/NE05276LOGO )
Dana Callow, Managing General Partner at Boston Millennia Partners said, "This high value sale was the result of Athenix's unique intellectual property, as well as superior execution of several development programs by its management team. We congratulate Athenix's Chief Executive, Michael Koziel, and his entire team for achieving this outstanding result."
Athenix discovers and develops proprietary productivity-enhancing crop traits for corn, soybean and other commercial crops. The management team spun out of DuPont Pioneer in 2001 and leveraged decades of experience in trait discovery to build a platform technology that created one of the largest libraries of agronomic traits in the industry. By making the strategic decision to establish partnerships with other industry participants, including DuPont, Syngenta, Monsanto, and others, Athenix was able to accelerate development, access distribution, build its balance sheet and achieve visibility with potential purchasers such as Bayer.
"Mike and his management team combined strong science and sound strategy to achieve this great result," said Rob Jevon, Boston Millennia Partner and Director of Athenix from inception of Millennia's Series A investment in Athenix. "BMP is proud to have been part of the Athenix story, whose products will provide significant benefits to farmers and consumers. We wish Mike and his team continued success with Bayer."
About Athenix
Athenix, founded in 2001, is a leading biotechnology company that develops novel products and technologies for agricultural and industrial applications. Athenix has established an outstanding intellectual property portfolio and market access ability around enhanced plants, microbes, genes, enzymes, and processes with emphasis on two major markets: 1) novel agricultural traits for growers such as insect resistance, nematode resistance, herbicide tolerance, and their use for the crop production industry; and 2) the discovery of genes and proteins for use in the sustainable chemical industry. For more information visit www.athenixcorp.com.
About Boston Millennia Partners
Boston Millennia Partners provides private equity financing to high growth companies in the healthcare, life sciences and business sciences sectors industry. Our team brings over one hundred years of combined private equity experience to the investment process. Our broad experience, combined with expertise in finance; operations; engineering; life sciences research and development; partnering with pharmaceutical companies; business development; executive recruiting; and law provides significant value to the companies in which we invest. Since the early 1980's, members of our team have managed seven venture capital partnerships with very successful results for our investors and our entrepreneurs. The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million under management.
www.bmpvc.com
SOURCE Boston Millennia Partners
http://www.bmpvc.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
